🔴 Rezolute is trading 5.3% down today as broader biotech weakness intensified

Rezolute is trading 5.3% down at $3.93 after broader biotech weakness intensified on September 16, 2026.

• The XBI biotech ETF is down 2.11% during regular trading, while major indexes are mostly higher, suggesting sector-specific pressure rather than broad-market selling.
• No new company-specific announcement or reported earnings result was identified on September 16.
• Investors remain focused on the unresolved FDA review of Rezolute’s Phase 3 sunRIZE data, announced September 9, which has no feedback timeline.